Nicox SA (OTCMKTS:NICXF – Free Report) – Stock analysts at HC Wainwright increased their Q1 2026 EPS estimates for Nicox in a research report issued on Friday, June 5th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.03) per share for the quarter, up from their previous estimate of ($0.04). The consensus estimate for Nicox’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Nicox’s Q2 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at $0.01 EPS.
Nicox Price Performance
NICXF stock opened at $0.30 on Tuesday. The firm has a 50-day simple moving average of $0.30 and a two-hundred day simple moving average of $0.30. Nicox has a one year low of $0.25 and a one year high of $0.30.
About Nicox
Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.
The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.
Read More
- Five stocks we like better than Nicox
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
